The IL-23/Th17 pathway inhibitors in the treatment of psoriasis and the risk of skin malignancies: a review
No finalized large-scale human clinical trials are published that demonstrate safety and efficacy in humans
B., Lippuner, K., Keel, M
Others may notice gradual improvement over the first few days
The answer is: it depends
Most importantly, numerous other neuroprotective and neurotrophic growth factors like BDNF-analogs and LM11A-31 are currently being studied for their cognitive and therapeutic benefits, especially their ability to preserve and promote neural networks and neuron health, particularly in the setting of neurodegenerative diseases like Alzheimer's disease, FrontoTemporal Dementia (FTD), Parkinson's Disease (PD), and Lewy-Body Disease, as well as ischemic or traumatic neural injury (68a) (68b) (68c) (68d)